Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.


Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences International Inc. (BDSI) Drops 6.72% on September 4

Equities.com September 4, 2014

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Ring The NASDAQ Stock Market Opening Bell

GlobeNewswire September 3, 2014

BioDelivery Sciences to Ring The NASDAQ Stock Market Opening Bell

PR Newswire September 3, 2014

BioDelivery Sciences to Host Investor and Analyst Event and Webcast Friday, September 5 on BUNAVAIL(TM) Launch and Pipeline

PR Newswire August 27, 2014

BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA

PR Newswire August 12, 2014

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials

PR Newswire August 7, 2014

BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy

PR Newswire August 6, 2014

BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors

PR Newswire July 22, 2014

Endo and BioDelivery Sciences announce positive top-line results from the Phase III clinical trial of BEMA® buprenorphine in opioid-experienced patients with chronic pain

PR Newswire July 7, 2014

BioDelivery Sciences Announces Completion of Patient Enrollment in its Initial Phase 3 Trial of Clonidine Topical Gel for Painful Diabetic Neuropathy

PR Newswire June 26, 2014

BioDelivery Sciences Featured on Bloomberg TV, TheStreet.com and Business News Network

PR Newswire June 11, 2014

BioDelivery Sciences to Present at the William Blair and Wells Fargo Healthcare Conferences

PR Newswire June 10, 2014

BioDelivery Sciences Receives FDA Approval for BUNAVAIL(TM) (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence

PR Newswire June 9, 2014

BioDelivery Sciences Receives FDA Approval for BUNAVAIL(TM) (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence

PR Newswire June 6, 2014

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials

PR Newswire May 8, 2014

BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

PR Newswire May 8, 2014

BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

PR Newswire May 6, 2014

BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference

PR Newswire April 7, 2014

BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

PR Newswire April 3, 2014

Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies

Business Wire April 1, 2014